Search Results

Successful Discontinuation of Glucocorticoid Treatment after Administration of a Calcineurin Inhibitor for Nephrotic Syndrome in a Patient with Lupus Nephritis.

• Authors : Sawamura M; Nephrology Center and Department of Rheumatology, Toranomon Hospital, Japan.; Sawa N

Subjects: Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/complications ; Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/drug therapy ; Nephrotic Syndrome*/Nephrotic Syndrome*/Nephrotic Syndrome*/complications

• Source: Internal medicine (Tokyo, Japan) [Intern Med] 2023 Apr 01; Vol. 62 (7), pp. 1037-1041. Date of Electronic Publication: 2022 Sep 06.Publisher: Japanese Society of Internal Medicine Country of Publication: Japan NLM ID: 9204241 Publication Model: Print-Electronic Cited Medium:

Record details

The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.

• Authors : Mandrik O; Health Economic and Decision Science, School of Health and Related Research, The University of Sheffield, Sheffield, United Kingdom.; Fotheringham J

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/economics ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Cyclosporine*/Cyclosporine*/Cyclosporine*/economics

• Source: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2022 Mar; Vol. 17 (3), pp. 385-394. Date of Electronic Publication: 2022 Feb 03.Publisher: American Society of Nephrology Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium:

Record details

The effectiveness and value of belimumab and voclosporin for lupus nephritis.

• Authors : Tice JA; Division of General Internal Medicine, University of California, San Francisco.; Mandrik O

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*economics ; Cyclosporine/Cyclosporine/Cyclosporine/*economics ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*economics

• Source: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2021 Oct; Vol. 27 (10), pp. 1495-1499.Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet

Record details

Voclosporin (Lupkynis) for lupus nephritis.

Subjects: Calcineurin Inhibitors/Calcineurin Inhibitors/Calcineurin Inhibitors/*administration & dosage ; Cyclosporine/Cyclosporine/Cyclosporine/*administration & dosage ; Lupus Nephritis/Lupus Nephritis/Lupus Nephritis/*drug therapy

• Source: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2021 Aug 23; Vol. 63 (1631), pp. 134-136.Publisher: The Medical Letter Country of Publication: United States NLM ID: 2985240R Publication Model: Print Cited Medium: Internet ISSN:

Record details

Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis.

• Authors : van Gelder T; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Lerma E

Subjects: Calcineurin Inhibitors*/Calcineurin Inhibitors*/Calcineurin Inhibitors*/adverse effects ; Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/drug therapy; Adult

• Source: Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2022 May; Vol. 15 (5), pp. 515-529. Date of Electronic Publication: 2022 Jul 11.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278296 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

• Authors : Rovin BH; Department of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.; Teng YKO

Subjects: Calcineurin Inhibitors/Calcineurin Inhibitors/Calcineurin Inhibitors/*administration & dosage ; Cyclosporine/Cyclosporine/Cyclosporine/*administration & dosage ; Lupus Nephritis/Lupus Nephritis/Lupus Nephritis/*drug therapy

• Source: Lancet (London, England) [Lancet] 2021 May 29; Vol. 397 (10289), pp. 2070-2080. Date of Electronic Publication: 2021 May 07.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X

Record details

Will New Treatment Options for Lupus Nephritis Be Affordable?

• Authors : Teng YKO; Center of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Disease, Department of Internal Medicine, Section of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; Rabelink TJ

Subjects: Lupus Erythematosus, Systemic* ; Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/drug therapy; Cyclosporine

• Source: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2022 Mar; Vol. 17 (3), pp. 340-341. Date of Electronic Publication: 2022 Feb 04.Publisher: American Society of Nephrology Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium:

Record details

From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?

• Authors : Parodis I; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Calcineurin Inhibitors/Calcineurin Inhibitors/Calcineurin Inhibitors/*therapeutic use ; Cyclosporine/Cyclosporine/Cyclosporine/*therapeutic use

• Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2022 Jan; Vol. 81 (1), pp. 15-19. Date of Electronic Publication: 2021 Sep 14.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060

Record details

Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.

• Authors : Lee YH; Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.; Song GG

Subjects: Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/chemically induced ; Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/drug therapy ; Mycophenolic Acid*/Mycophenolic Acid*/Mycophenolic Acid*/adverse effects

• Source: Pharmacology [Pharmacology] 2022; Vol. 107 (9-10), pp. 439-445. Date of Electronic Publication: 2022 May 24.Publisher: Karger Country of Publication: Switzerland NLM ID: 0152016 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0313

Record details

How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.

• Authors : van Gelder T; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: .

Subjects: Calcineurin Inhibitors*/Calcineurin Inhibitors*/Calcineurin Inhibitors*/adverse effects ; Lupus Nephritis*/Lupus Nephritis*/Lupus Nephritis*/drug therapy; Adult

• Source: Kidney international [Kidney Int] 2021 Dec; Vol. 100 (6), pp. 1185-1189. Date of Electronic Publication: 2021 Jul 17.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details